Who are clarithromycin-based triple therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clarithromycin-based-triple-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

clarithromycin-based triple therapy — Competitive Intelligence Brief

clarithromycin-based triple therapy (clarithromycin-based triple therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic combination therapy. Area: Gastroenterology / Infectious Disease.

marketed Macrolide antibiotic combination therapy Bacterial 50S ribosome (clarithromycin component) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

clarithromycin-based triple therapy (clarithromycin-based triple therapy) — National Taiwan University Hospital. Clarithromycin-based triple therapy combines a macrolide antibiotic with two other agents (typically a proton pump inhibitor and amoxicillin or metronidazole) to eradicate Helicobacter pylori infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
clarithromycin-based triple therapy TARGET	clarithromycin-based triple therapy	National Taiwan University Hospital	marketed	Macrolide antibiotic combination therapy	Bacterial 50S ribosome (clarithromycin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic combination therapy class)

National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). clarithromycin-based triple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/clarithromycin-based-triple-therapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab